PCA demonstrates the distinct clustering of GRN+/+ and GRN+/− proteomes as well as the correction seen with A41 treatment (Fig. 6I), adding further evidence to the validity of our compounds as therapies for GRN-FTD. This evidence concerns the gene GRN and frontotemporal dementia.